基本信息:
- 专利标题： ISOLATION AND IDENTIFICATION OF CROSS-REACTIVE T CELLS
- 专利标题（中）：交叉反应性T细胞的分离和鉴定
- 申请号：PCT/US0341284 申请日：2003-12-23
- 公开(公告)号：WO2004060145A3 公开(公告)日：2004-10-28
- 发明人： ZHANG JINGWU
- 申请人： BAYLOR COLLEGE MEDICINE , OPEXA PHARMACEUTICALS INC , ZHANG JINGWU
- 专利权人： BAYLOR COLLEGE MEDICINE,OPEXA PHARMACEUTICALS INC,ZHANG JINGWU
- 当前专利权人： BAYLOR COLLEGE MEDICINE,OPEXA PHARMACEUTICALS INC,ZHANG JINGWU
- 优先权： US43736902 2002-12-31
- 主分类号： A61B
- IPC分类号： A61B20060101 ; A61K39/00 ; C07H21/04 ; C12N5/00 ; C12N5/02 ; C12N5/08 ; C12P21/06 ; G01N33/564
摘要：
Cross-reactive T cells recognizing both MBP93-105 and HHV-61-13 peptides represent a significant subset of T cells with some degree of TCR degeneracy. It appears that the recognition of the cross-reactive T cells has a less stringent requirement for the flanking residues of the two peptides. In contrast, these flanking residues are critical for the T cell recognition of mono-specific T cells. The association between HHV-6 and autoreactive immune responses to MBP indicates that cross-reactive T cells, peptides from the V-D-J region of the T cell receptor from autoreactive T cells, and antiviral agents may prevent or treat MS.
摘要（中）：
识别MBP93-105和HHV-61-13肽的交叉反应性T细胞代表具有某种程度TCR简并性的T细胞的重要子集。 似乎交叉反应性T细胞的识别对两种肽的侧翼残基的要求不太严格。 相反，这些侧翼残基对T细胞识别单特异性T细胞至关重要。 HHV-6与对MBP的自体反应性免疫反应之间的关联表明交叉反应性T细胞，来自自身反应性T细胞的T细胞受体的V-D-J区的肽和抗病毒剂可预防或治疗MS。